Recombinant Anti-p57 Kip2 Antibody [KIP2/8169R] (A315444)

Anti-p57 Kip2 Antibody [KIP2/8169R]

Recombinant rabbit monoclonal [KIP2/8169R] antibody to p57 Kip2.

Recognizes a protein of 57kDa, identified as p57Kip2. It shows no cross-reaction with p27Kip1. p57Kip2 is a potent tight-binding inhibitor of several G1 cyclin complexes, and is a negative regulator of cell proliferation. Anti-p57 has been used as an aide in identification of complete hydatidiform mole (CHM) (no nuclear labeling of cytotrophoblasts and stromal cells) from partial hydatidiform mole (PHM) in which both cytotrophoblasts and stromal cells stain. The histological differentiation of complete mole, partial mole, and hydropic spontaneous abortion is problematic. Most complete hydatidiform moles are diploid, whereas most partial moles are triploid. Ploidy studies will identify partial moles, but will not differentiate complete moles from non-molar gestations. Complete moles carry a high risk of persistent disease and choriocarcinoma, while partial moles have a very low risk. In normal placenta, many cytotrophoblast nuclei and stromal cells are labeled with this antibody. Similar findings apply to PHM and hydropic abortus tissues. Intervillous trophoblastic islands (IVTIs) demonstrate nuclear labeling in all three entities and serve as an internal control.

Raji, HT29 or SK-BR3 cells. Human colon or prostate carcinomas.

IHC: 0.25-0.5 µg/ml

Human

Recombinant full-length human p57Kip2 protein.

Rabbit

Monoclonal

KIP2/8169R

kappa

Unconjugated

Protein A/G chromatography.

200 µg/ml

57 kDa

Liquid

Supplied in 10mM Phosphate Buffered Saline with 0.05% BSA and 0.05% Sodium Azide.

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Beckwith Wiedemann syndrome, BWCR, BWS, CDKI, CDKN 1C, CDKN1C, CDN1C_HUMAN, Cyclin dependent kinase inhibitor 1C, Cyclin dependent kinase inhibitor p57, Cyclin-dependent kinase inhibitor 1C, Cyclin-dependent kinase inhibitor p57, KIP 2, KIP2, p57, p57 Kip 2, p57KIP2, WBS